LI

LF Investment

Europe, Hovedstaden, Denmark, Hellerup

Description

LF Investment is the investment arm of The Lauritzen Foundation.

Investor Profile

LF Investment has made 4 investments, with 0 in the past 12 months and 25% as lead.

Stage Focus

  • Series Unknown (50%)
  • Series C (25%)
  • Series B (25%)

Country Focus

  • Denmark (100%)

Industry Focus

  • Biotechnology
  • Health Care
  • Life Science
  • Medical
  • Wellness
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does LF Investment frequently co-invest with?

Wellington Partners
Europe, Bayern, Germany, Munich
Co-Investments: 3
Trill Impact
Europe, Stockholms Lan, Sweden, Stockholm
Co-Investments: 2
Industrifonden
Europe, Stockholms Lan, Sweden, Stockholm
Co-Investments: 3
Novo Holdings
Europe, Hovedstaden, Denmark, Hellerup
Co-Investments: 2
Pureos Bioventures
Europe, Zurich, Switzerland, Küsnacht
Co-Investments: 2
EQT Life Sciences
Europe, Noord-Holland, The Netherlands, Amsterdam
Co-Investments: 1
Adjuvant Capital
North America, New York, United States, New York
Co-Investments: 3
Sanofi Ventures
North America, Massachusetts, United States, Cambridge
Co-Investments: 3
RI
Europe, Hovedstaden, Denmark, Hellerup
Co-Investments: 2
Sunstone Life Science Ventures
Europe, Hovedstaden, Denmark, Copenhagen
Co-Investments: 4

What are some of recent deals done by LF Investment?

Minervax

Hellerup, Hovedstaden, Denmark

Minervax is a biotechnology company developing a novel vaccine against Group B Streptococcus.

BiotechnologyHealth CareLife ScienceMedicalWellness
Series UnknownOct 11, 2023
Amount Raised: $57,367,288
Minervax

Hellerup, Hovedstaden, Denmark

Minervax is a biotechnology company developing a novel vaccine against Group B Streptococcus.

BiotechnologyHealth CareLife ScienceMedicalWellness
Series CDec 15, 2022
Amount Raised: $23,405,251
Minervax

Hellerup, Hovedstaden, Denmark

Minervax is a biotechnology company developing a novel vaccine against Group B Streptococcus.

BiotechnologyHealth CareLife ScienceMedicalWellness
Series BDec 15, 2020
Amount Raised: $57,612,508
Minervax

Hellerup, Hovedstaden, Denmark

Minervax is a biotechnology company developing a novel vaccine against Group B Streptococcus.

BiotechnologyHealth CareLife ScienceMedicalWellness
Series UnknownFeb 15, 2016
Amount Raised: $2,454,990